Optomed announces a fixed subscription price for its initial public offering and further information about the listing of its shares
Optomed has announced the subscription price for the share issue in connection with its initial public offering. The company stated on 8 November 2019 that it is planning the IPO and the listing of its shares on the official list of Nasdaq Helsinki Ltd.The Finnish Financial Supervisory Authority has approved Optomed’s Finnish language prospectus, which was published on 22 November 2019. The subscription period for the offering commenced on the same day.
Background and reasons for the Offering and Listing
The objective of the contemplated Offering and Listing is to improve the Company’s ability to successfully pursue its growth strategy and invest in its business in order to remain at the forefront of developing complete screening solutions against blinding eye diseases and expand into new markets. The contemplated Offering and Listing on Nasdaq Helsinki will also allow Optomed to obtain access to capital markets and broaden its ownership base with both domestic and foreign investor, which would increase the liquidity of the Shares. Furthermore, the Offering is expected to strengthen Optomed’s recognition and brand awareness among customers, business partners and investors, and thus enhance Optomed’s competitiveness and the market’s awareness of handheld fundus cameras. The increased liquidity would also enable Optomed to use the Shares more effectively as a means of consideration in potential acquisitions and remuneration of personnel.
Read more information here.